Anaïs Schavgoulidze

Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor

Anaïs Schavgoulidze, Alexis Talbot, Aurore Perrot et al. · Blood · 2022 · 62 citations · Full text

Medicine, Hematology, Oncology +8

In Multiple Myeloma, High-Risk Secondary Genetic Events Observed at Relapse Are Present From Diagnosis in Tiny, Undetectable Subclonal Populations

Romain Lannes, Mehmet Samur, Aurore Perrot et al. · Journal of Clinical Oncology · 2022 · 45 citations · Full text

Medicine, Genetics, Molecular Genetics +17

Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical features

Titouan Cazaubiel, Xavier Leleu, Aurore Perrot et al. · Blood · 2022 · 29 citations · Full text

Medicine, Hematology, Oncology +14

Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma

Anaïs Schavgoulidze, Valérie Lauwers‐Cancès, Aurore Perrot et al. · Haematologica · 2022 · 18 citations · Full text

Medicine, Hematology, Oncology +16

<i>RAS/RAF</i> landscape in monoclonal plasma cell conditions

Anaïs Schavgoulidze, Jill Corre, Mehmet Samur et al. · Blood · 2024 · 11 citations · Full text

Medicine, Hematology, Oncology +15